Loading
Mecapegfilgrastim is Hengrui's long-acting G-CSF, approved in China in 2018 to prevent chemotherapy-induced neutropenia.
Mecapegfilgrastim (Aiduo) is a long-acting pegylated G-CSF developed by Jiangsu Hengrui. The NMPA approved it in May 2018 to reduce the incidence and duration of neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid cancers. It is one of the most widely used supportive-care biologics in China.
A pegylated form of G-CSF that tells the bone marrow to make neutrophils, shortening the low-neutrophil period after chemotherapy.
1.Mecapegfilgrastim slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2018 | Prevention of chemotherapy-induced neutropenia in non-myeloid cancers |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Mecapegfilgrastim" OR ABSTRACT:"Mecapegfilgrastim" OR TITLE:"HHPG-19K" OR ABSTRACT:"HHPG-19K" OR TITLE:"Aiduo" OR ABSTRACT:"Aiduo" OR TITLE:"19K" OR ABSTRACT:"19K") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mecapegfilgrastim, not a curated reading list.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.
Shares the tags china, nmpa-approved.